Furthermore, the PI3K/AKT pathway is highly involved in the development of multidrug resistance in cancer, including ovarian cancer, thus the inhibition of this pathway is considered to be a promising therapeutic strategy [59,60]. This evidence concerns the gene AKT1 and cancer.